Dramatic response to alectinib in a lung cancer patient with a novel VKORC1L1-ALK fusion and an acquired ALK T1151K mutation

ALK-rearranged lung cancer defines a distinctive molecular cohort of patients whose outcomes are significantly improved by the availability of ALK inhibitors. Thus, it is imperative for clinicians to screen appropriate patients for this driver mutation with a molecular testing platform capable of ca...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Lung Cancer (Auckl)
Asıl Yazarlar: Zhu, Viola W, Schrock, Alexa B, Bosemani, Thangavijayan, Benn, Bryan S, Ali, Siraj M, Ou, Sai-Hong Ignatius
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove Medical Press 2018
Konular:
Case Report
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6234987/
https://ncbi.nlm.nih.gov/pubmed/30519133
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/LCTT.S186804
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller